Human Growth Hormone (HGH) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Long Acting, Others), By Application (Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.78 Billion
CAGR (2026-2031)	13.92%
Fastest Growing Segment	Specialty Pharmacy
Largest Market	North America
Market Size (2031)	USD 14.82 Billion

Market Overview

The Global Human Growth Hormone (HGH) Market is projected to grow from USD 6.78 Billion in 2025 to USD 14.82 Billion by 2031 at a 13.92% CAGR. The Global Human Growth Hormone (HGH) Market centers on somatropin, a recombinant peptide hormone essential for stimulating physical growth, cell reproduction, and regeneration in humans. The primary drivers supporting market expansion include the rising prevalence of congenital growth hormone deficiency, Turner syndrome, and Prader-Willi syndrome, coupled with increased clinical recognition of adult-onset deficiencies. These fundamental factors create robust demand as healthcare providers prioritize early intervention for developmental disorders. According to the MAGIC Foundation, in 2025, approximately 48 percent of children evaluated for the two most common causes of growth failure remained undiagnosed, underscoring a significant unmet need that continues to propel therapeutic adoption.

Conversely, a significant challenge impeding market proliferation is the high cost of treatment and the stringent reimbursement criteria imposed by payers. Insurance providers frequently enforce rigorous prior authorization protocols to manage expenses and prevent off-label usage, which restricts patient access to these high-value biologics. This financial barrier serves as a notable restraint, particularly in regions with limited healthcare funding, effectively slowing the potential trajectory of global market saturation despite the clear clinical demand.

Key Market Drivers

The development of long-acting and novel drug delivery systems is fundamentally reshaping the Global Human Growth Hormone Market by addressing the historical challenge of treatment adherence. By transitioning from daily injections to once-weekly administration these advancements significantly reduce the treatment burden for patients which accelerates the adoption of premium biologic therapies. This shift towards patient-centric delivery mechanisms is rapidly translating into substantial revenue growth for innovators in the space. According to Ascendis Pharma in February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company reported that its long-acting therapy Skytrofa achieved full-year 2024 revenue of approximately 202 million Euros. Such financial milestones underscore the market potency of next-generation formulations as they progressively replace traditional daily somatropin injections.

Increasing prevalence of growth hormone deficiency disorders further serves as a primary catalyst for sustained market expansion as improved diagnostic screening identifies more patients requiring long-term therapy. The rising incidence of congenital pituitary defects and acquired deficiencies necessitates continuous endocrine management thereby widening the addressable market. According to the journal Endocrine in March 2024, in the article 'Epidemiology of growth hormone deficiency in children and adolescents', a systematic review indicated that the prevalence of the condition in children ranges between 1 in 1107 and 1 in 8646 individuals. This expanding patient base ensures robust demand for established treatments. According to Novo Nordisk in 2025, the company reported that its rare disease segment which is largely comprised of growth hormone products generated 18.64 billion Danish Krone in sales for the 2024 fiscal year.

Download Free Sample Report

Key Market Challenges

The high cost of treatment and the stringent reimbursement criteria imposed by payers act as a substantial restraint on the Global Human Growth Hormone (HGH) Market. Insurance providers frequently enforce rigorous prior authorization protocols and restrictive formulary lists to mitigate the expenses associated with these high-value biologics. These administrative hurdles often disrupt the continuum of care, causing significant delays or denials for pediatric patients who possess a critical, time-limited window for effective growth stimulation. Consequently, the difficulty in securing and maintaining coverage discourages long-term adherence and reduces the total volume of dispensed prescriptions, effectively neutralizing the demand generated by improved diagnosis rates.

This persistent financial friction prevents the market from reaching its full commercial potential by limiting the addressable patient pool to only those with robust insurance approval. According to the PAN Foundation, in 2025, the State of Patient Access Scorecard reported that access to treatment through healthcare plans received a critically low score of 63.1, indicating that insurance barriers remain a primary obstacle for patients requiring specialty medications. This data underscores a structural impediment where stringent payer policies directly limit patient uptake, thereby slowing the overall revenue trajectory of the market despite the clear clinical necessity for these therapies.

Key Market Trends

The increasing commercialization of cost-effective biosimilars is fundamentally altering the competitive landscape of the Global Human Growth Hormone (HGH) Market as patent expiries for originator biologics enable the entry of lower-priced alternatives. Payers and healthcare systems are aggressively prioritizing these therapeutically equivalent options to mitigate the substantial financial burden associated with long-term endocrine therapies, thereby driving a volume-based shift away from premium branded products. This market dynamic is evidenced by the robust financial performance of leading biosimilar developers who are capturing significant market share through competitive pricing strategies. According to Sandoz, March 2025, in the 'Full Year 2024 Financial Results', the company reported that its biosimilars division achieved sales of USD 2.85 billion, representing a 30 percent increase driven significantly by the continued strong demand for its somatropin biosimilar, Omnitrope.

Simultaneously, the expansion of clinical indications to adult growth hormone deficiency is widening the addressable patient population beyond the traditional pediatric segment. Pharmaceutical companies are securing regulatory approvals for adult-specific dosing and indications, acknowledging the critical role of growth hormone in managing metabolic health, body composition, and quality of life in mature patients with pituitary disorders. This strategic pivot transforms the market from a time-limited pediatric intervention to a potential lifelong chronic care model. According to Ascendis Pharma, July 2025, in the press release 'FDA Approves SKYTROFA for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency', the company announced the label expansion for its long-acting therapy based on the Phase 3 foresiGHt trial, which evaluated clinical efficacy in 259 adult patients.

Segmental Insights

According to market research, the Specialty Pharmacy segment is emerging as the fastest growing distribution channel within the Global Human Growth Hormone (HGH) Market. This rapid expansion is primarily driven by the complex handling requirements of HGH biologics, which necessitate stringent cold chain management and storage conditions that specialty pharmacies are uniquely equipped to maintain. Furthermore, these institutions provide essential patient support services, including education on injection techniques and adherence monitoring, which are critical for effective treatment. The segment also benefits from dedicated expertise in navigating intricate insurance reimbursement processes and securing prior authorizations for high-value therapies.

Regional Insights

North America dominates the global Human Growth Hormone market, driven primarily by the rising prevalence of growth hormone deficiencies and Turner syndrome within the general population. The region benefits significantly from a well-established healthcare infrastructure that facilitates early diagnosis and consistent treatment. Additionally, the presence of major pharmaceutical manufacturers ensures widespread product availability and distribution. Favorable reimbursement policies in the United States further support market expansion by improving patient access to these therapies. Finally, the US Food and Drug Administration plays a critical role in maintaining market stability through the regular approval of new indications.

Recent Developments

• In October 2025, Novo Nordisk announced the commercial availability of Sogroya in Canada for the treatment of both pediatric and adult growth hormone deficiency. This launch established the product as the first and only once-weekly growth hormone therapy available for both age groups in the Canadian market. The company aims to enhance patient adherence and quality of life by reducing the injection frequency from a daily routine to a single weekly dose. The availability of this long-acting formulation represents a strategic expansion of the company’s rare disease portfolio, offering a modern therapeutic option for individuals requiring long-term growth hormone replacement.
• In July 2025, Ascendis Pharma received approval from the U.S. Food and Drug Administration for Skytrofa to treat adults with growth hormone deficiency. This decision was based on the successful outcomes of the Phase 3 foresiGHt trial, which demonstrated that the once-weekly therapy significantly reduced trunk fat and improved body composition compared to placebo. The approval allows the company to extend the commercial reach of its proprietary TransCon technology beyond the pediatric market. The company’s leadership emphasized that this label expansion addresses a critical unmet need for adult patients seeking a less burdensome treatment alternative to daily injections.
• In May 2025, Novo Nordisk released positive results from the Phase 3 REAL8 basket study, which evaluated the efficacy and safety of its once-weekly Sogroya injection in children with various growth disorders. The data, presented at a major endocrinology congress, showed that the treatment was non-inferior to daily somatropin in improving height velocity for patients born small for gestational age, with Noonan syndrome, or with idiopathic short stature. The company highlighted that the safety profile was consistent with existing therapies, with no new tolerability issues identified. These findings support regulatory applications to expand the use of the long-acting growth hormone analog to broader pediatric populations.
• In March 2024, Visen Pharmaceuticals announced that the National Medical Products Administration (NMPA) in China accepted the Biologics License Application for lonapegsomatropin for the treatment of pediatric growth hormone deficiency. This regulatory milestone marks a significant advancement for the company in the Greater China market, where it holds exclusive rights to develop and commercialize the therapy. The submission was supported by results from a Phase 3 trial in China, which demonstrated that the once-weekly prodrug delivered statistically significant improvements in annualized height velocity compared to daily somatropin. The acceptance brings the company closer to introducing a new standard of care for patients requiring growth hormone replacement.

Key Market Players

• Novo Nordisk A/S
• Eli Lilly and Company
• Pfizer, Inc.
• Sandoz International GmbH
• Genentech, Inc.
• Merck KGaA
• Ferring Holding S.A.
• Ipsen S.A.
• Teva Pharmaceutical Industries, Ltd.

By Product	By Application	By Distribution Channel	By Region
Long Acting Others	Growth Hormone (GH) Deficiency Turner Syndrome Idiopathic Short Stature Prader-Willi Syndrome Small for Gestational Age Other	Hospital Pharmacy Retail Pharmacy Online Pharmacy Specialty Pharmacy	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Human Growth Hormone (HGH) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Human Growth Hormone (HGH) Market, By Product:

• Long Acting
• Others

• Human Growth Hormone (HGH) Market, By Application:

• Growth Hormone (GH) Deficiency
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Small for Gestational Age
• Other

• Human Growth Hormone (HGH) Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Specialty Pharmacy

• Human Growth Hormone (HGH) Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE